Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COMMENTARY
COMMENTARY
-
Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
February 21, 2011
-
Recent Topics in Promising Anticancer Therapeutics
January 17, 2011
-
Development Race for Oral Anticoagulants Entering Final Stretch
October 11, 2010
-
How to Eliminate Concerns about Safety of Liovel
October 4, 2010
-
Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
September 20, 2010
-
Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
September 13, 2010
-
Prior Assessment System Is One Step Forward to Quicker NDA Review
August 2, 2010
-
Industry Needs to Form Consensus on Premium with Med. Institutions
July 26, 2010
-
Japan Should Promote Personalized Cancer Treatment
July 26, 2010
-
METI Reports on “Patent Box”Taxation System in Its Vision 2010
July 5, 2010
-
How Will Generics-Only Companies Will Compete with Major New Entrants?
June 28, 2010
-
Mr Hasegawa Calls For Cooperation with Asian Countries
June 21, 2010
-
PMDA Consultation for Clinical Drug Development in Japan
April 26, 2010
-
Taiyo Needs to Restart from Scratch
April 19, 2010
-
Drug Companies Have No Time to Lose under New Pricing System
March 29, 2010
-
Wholesalers, Pharmacy Chains to Ally to Improve Their Business
March 22, 2010
-
New Pricing System Gives Makers Good Chance to Break from Old Business Practices
March 8, 2010
-
Transfer Limited Financial Resources to Parties Who Make Effort to Provide Better Services
March 1, 2010
-
Korosho Moves to Change Its Vaccine Policy
February 22, 2010
-
Prospects of the Japanese Pharmaceutical Industry in 2010
February 15, 2010
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…